We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $269M
1-Year Est. Return 103.38%
This Fund
S&P 500
This Quarter Est. Return
+8.81%
1 Year Est. Return
+103.38%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$211M
AUM Growth
+$5.25M
Cap. Flow
+$4.92K
Cap. Flow %
0%
Top 10 Hldgs %
62.31%
Holding
46
New
12
Increased
7
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$13.9M
2
RZLT icon
Rezolute
RZLT
+$6.47M
3
DCTH icon
Delcath Systems
DCTH
+$5.58M
4
CGON icon
CG Oncology
CGON
+$4.65M
5
MYO icon
Myomo
MYO
+$3.23M

Top Sells

Rank Stock Value
1
ABEO icon
Abeona Therapeutics
ABEO
+$8.6M
2
NUVB icon
Nuvation Bio
NUVB
+$4.31M
3
URGN icon
UroGen Pharma
URGN
+$3.91M
4
VSTM icon
Verastem
VSTM
+$3.76M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$3.62M

Sector Composition

Rank Sector Weight
1 Healthcare 97.99%
2 Miscellaneous 2.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCTH icon
1
Delcath Systems
DCTH
$567M
$33M 15.65%
3,300,389
+400,000
+14% +$5.58M
FENC icon
2
Fennec Pharmaceuticals
FENC
$430M
$17M 8.05%
2,045,644
+262,800
+15% +$1.8M
CYTK icon
3
Cytokinetics
CYTK
$10B
$13.2M 6.27%
+400,000
New +$13.9M
OCUL icon
4
Ocular Therapeutix
OCUL
$2.28B
$11.3M 5.36%
1,218,700
– –
IDYA icon
5
IDEAYA Biosciences
IDYA
$3.87B
$10.7M 5.09%
511,132
-188,868
-27% -$3.62M
XERS icon
6
Xeris Biopharma Holdings
XERS
$1.55B
$10.1M 4.77%
2,155,594
-340,392
-14% -$1.56M
VRDN icon
7
Viridian Therapeutics
VRDN
$2.61B
$9.79M 4.64%
700,000
+105,000
+18% +$1.43M
VRNA
8
DELISTED
Verona Pharma
VRNA
$9.46M 4.48%
100,000
– –
VSTM icon
9
Verastem
VSTM
$654M
$8.48M 4.02%
2,043,563
-600,954
-23% -$3.76M
REPL icon
10
Replimune Group
REPL
$1.46B
$8.36M 3.96%
900,000
+50,000
+6% +$436K
MDWD icon
11
MediWound
MDWD
$163M
$7.88M 3.74%
407,061
-99,832
-20% -$1.88M
MYO icon
12
Myomo
MYO
$63.4M
$7.77M 3.68%
3,595,788
+892,127
+33% +$3.23M
RZLT icon
13
Rezolute
RZLT
$445M
$7.77M 3.68%
+1,741,211
New +$6.47M
URGN icon
14
UroGen Pharma
URGN
$2.13B
$7.43M 3.52%
542,366
-407,634
-43% -$3.91M
HELP
15
Cybin Inc
HELP
$890M
$6.8M 3.23%
810,918
– –
SVRA icon
16
Savara
SVRA
$1.08B
$6.05M 2.87%
2,654,944
– –
NSPR icon
17
InspireMD
NSPR
$39.8M
$5.2M 2.46%
2,289,099
+14,109
+0.6% +$35.2K
CGON icon
18
CG Oncology
CGON
$6.59B
$5.02M 2.38%
+192,974
New +$4.65M
PROF
19
Profound Medical
PROF
$250M
$4.08M 1.94%
692,185
– –
PHVS icon
20
Pharvaris
PHVS
$2.48B
$3.94M 1.87%
223,627
– –
PYPD icon
21
PolyPid
PYPD
$103M
$3.44M 1.63%
975,462
-42,559
-4% -$125K
DFTX
22
Definium Therapeutics
DFTX
$5.51B
$2.73M 1.29%
420,000
– –
KALV
23
DELISTED
KalVista Pharmaceuticals
KALV
$1.78M 0.85%
157,725
-146,139
-48% -$1.79M
INMB icon
24
PUT
INmune Bio
INMB
$64.7M
$1.76M 0.84%
+1,033,200
New +$7.58M
TRVI icon
25
Trevi Therapeutics
TRVI
$2.39B
$1.64M 0.78%
300,000
-312,901
-51% -$1.95M
1
2

Similar funds

GPFA
Game Plan Financial Advisors Westlake, Ohio $269M AUM 28.74% 1-Year Est. Return
AFO
Allie Family Office Miami, Florida $269M AUM 20.2% 1-Year Est. Return
TW
Titan Wealth St Peter Port $269M AUM
PM
Plustick Management Charlottesville, Virginia $269M AUM 340.55% 1-Year Est. Return
ZEP
Zeno Equity Partners London, United Kingdom $269M AUM 6.35% 1-Year Est. Return
LBW
Landesbank Baden-Wuerttemberg Stuttgart Baden-Wuerttemberg, Germany $269M AUM
VP
Verisail Partners Chamblee, Georgia $270M AUM 16.03% 1-Year Est. Return
5W
5T Wealth Napa, California $269M AUM 17.81% 1-Year Est. Return

Rosalind Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Rosalind Advisors held 46 positions worth $211M, up 2.6% from $206M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Rosalind Advisors's Q2 2025 filing shows 12 new, 7 increased, 9 reduced and 9 closed positions. Its largest new stake was Cytokinetics: 400,000 shares worth $13.2M. The largest sale was Abeona Therapeutics, an estimated $8.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • Rosalind Advisors's largest Q2 2025 buy was Cytokinetics: 400,000 shares worth $13.2M.
  • Rosalind Advisors added most to Delcath Systems in Q2 2025, an estimated $5.58M increase.
  • Rosalind Advisors's biggest Q2 2025 reduction was UroGen Pharma, cutting an estimated $3.91M.
  • Rosalind Advisors fully exited Abeona Therapeutics in Q2 2025, selling an estimated $8.6M.
  • Rosalind Advisors's ten largest holdings make up 62% of its $211M portfolio in Q2 2025.
  • Rosalind Advisors opened 12 new positions and closed 9 in Q2 2025.
  • Rosalind Advisors's portfolio value rose 2.6% quarter-over-quarter to $211M.

Based on Rosalind Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.